Heart Failure
The year in obesity: New data on semaglutide and tirzepatide, sarcopenic obesity and more
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.
Weight gain after breast cancer diagnosis linked to greater heart failure risk
Weight gain after a breast cancer diagnosis elevated a person’s risk for heart failure, according to results of an observational study in the Republic of Korea.
Lower fracture, higher cardiovascular risks seen with denosumab for patients on dialysis
Among adults with osteoporosis on dialysis, use of denosumab significantly lowered fracture risk compared with bisphosphonate use, but cardiovascular risk was increased, according to study data.
Awareness of sex-specific differences in heart failure ‘critical’ for diagnosis, treatment
Women with heart failure with preserved ejection fraction have sex-specific differences in presentation, diagnosis and treatment responses, highlighting the importance of proper diagnoses and guideline-directed medical therapy initiation.
Top in cardiology: Wegovy tied to lower medical costs; race not necessary in MESA score
A real-world study of patients with overweight or obesity and heart failure demonstrated that initiation of semaglutide 2.4 mg corresponded with a mean total medical cost reduction of $6,512 during a 1-year follow-up period.
Millions of American adults face a 10% or higher risk for heart failure
As many as 15 million adults in the United States have a 10% or greater risk for heart failure, results of a research letter published in Annals of Internal Medicine showed.
Heart pumps’ indication expanded to pediatric patients with HF, cardiogenic shock
Johnson & Johnson MedTech announced the FDA has approved an expanded indication and granted premarket approval for its heart pumps to be used to treat pediatric patients with symptomatic acute decompensated HF and cardiogenic shock.
Early menopause tied to higher risk for incident heart failure
Women with menopause onset before age 45 years were more likely to develop incident heart failure regardless of serum adipokine levels, according to study findings published in Menopause.
Wegovy linked to real-world medical cost savings for people with obesity, heart failure
SAN ANTONIO — Semaglutide 2.4 mg was associated with reduced year-over-year health care costs, up to $6,500, among patients with overweight or obesity and heart failure, a speaker reported.
‘Dealing with a time bomb’: Persistent tobacco smoking tied to cardiac injury at young age
In a cohort of English youths, those who persisted smoking tobacco from childhood to early adulthood showed significant cardiac damage by age 24 years and potentially irreversible cardiac injury, a researcher reported.